OUTLOOK: Japanese Pharma Anticipates Varying Fortunes
This article was originally published in PharmAsia News
Japanese pharma companies have begun reporting their annual results for the fiscal year ending Mar. 31, and while the numbers appear to be generally in line with expectations, Takeda will be hard hit by the settlement for Actos. Guidance from other firms for the current year has also raised some analyst eyebrows.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.